NCT05752149 (STELLAR) is a Phase 2 clinical trial of CRGD-ZW800-1 in Squamous Cell Carcinoma of the Larynx, sponsored by Erasmus Medical Center.

Who is sponsoring NCT05752149?

NCT05752149 is sponsored by Erasmus Medical Center.

What drugs are being tested in NCT05752149?

Interventions in NCT05752149: CRGD-ZW800-1.

What condition does NCT05752149 study?

NCT05752149 studies Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx.

Is NCT05752149 still recruiting?

NCT05752149 is currently not yet recruiting. Last updated 26 February 2025.

Last reviewed 2025-02-26 · How we verify

NCT05752149: STELLAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial

Not yet recruiting Phase 2 Last updated 26 February 2025

What this trial tests

Phase 2 trial testing CRGD-ZW800-1 in Squamous Cell Carcinoma of the Larynx in 27 participants. Not yet recruiting.

Timeline

1 June 2025

Primary endpoint
1 February 2027

1 March 2027

Quick facts

Lead sponsor	Erasmus Medical Center
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	single
Primary purpose	diagnostic
Enrollment	27
Start date	1 June 2025
Primary completion	1 February 2027
Estimated completion	1 March 2027
Sites	1 location across Netherlands

Drugs / interventions tested

CRGD-ZW800-1 — full drug profile →

Conditions studied

Squamous Cell Carcinoma of the Larynx — all drugs for Squamous Cell Carcinoma of the Larynx →
Squamous Cell Carcinoma of the Hypopharynx — all drugs for Squamous Cell Carcinoma of the Hypopharynx →

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Squamous Cell Carcinoma of the Larynx or Squamous Cell Carcinoma of the Hypopharynx. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Harnessing Photo-Energy Conversion in Nanomaterials for Precision Theranostics.
Shi J, Fan Y, Zhang Q, Huang Y, et al · · 2025 · cited 4× · PMID 40376855 · DOI 10.1002/adma.202501623
Identifying Molecular Probes for Fluorescence-Guided Surgery in Neuroblastoma: A Systematic Review.
Hennessy M, Neville JJ, Privitera L, Sedgwick A, et al · · 2025 · PMID 40426729 · DOI 10.3390/children12050550

Verify or expand the search:

Other trials of CRGD-ZW800-1

Trials testing the same drug.

NCT05518071 — FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 · Phase 2 · completed

Other recruiting trials for Squamous Cell Carcinoma of the Larynx

Currently open trials in the same condition.

NCT03114462 — Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer · Phase 1 · recruiting

Other Erasmus Medical Center trials

Trials by the same sponsor.

NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05752149 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
Last refreshed: 26 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05752149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing